Sumitomo Life Insurance Co. Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Sumitomo Life Insurance Co. purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor purchased 2,118 shares of the biopharmaceutical company’s stock, valued at approximately $691,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. SVB Wealth LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $27,000. Ameritas Advisory Services LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $42,000. AlphaQuest LLC purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $43,000. Steph & Co. purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at about $60,000. Finally, Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 77.8% in the 2nd quarter. Bessemer Group Inc. now owns 192 shares of the biopharmaceutical company’s stock valued at $63,000 after buying an additional 84 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.4%

Shares of NASDAQ:ALNY opened at $456.04 on Monday. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market capitalization of $59.78 billion, a PE ratio of -184.63 and a beta of 0.36. The firm’s 50-day moving average is $460.19 and its two-hundred day moving average is $370.92. Alnylam Pharmaceuticals, Inc. has a 1 year low of $205.87 and a 1 year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.39 by $1.51. The company had revenue of $1.25 billion for the quarter, compared to analyst estimates of $943.37 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business’s revenue for the quarter was up 149.3% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.50) earnings per share. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity

In related news, EVP Jeffrey V. Poulton sold 3,821 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. This represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Tolga Tanguler sold 1,405 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total transaction of $635,130.25. Following the sale, the executive vice president owned 27,438 shares in the company, valued at $12,403,347.90. The trade was a 4.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently issued reports on ALNY shares. The Goldman Sachs Group boosted their price objective on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the company a “buy” rating in a report on Tuesday, September 16th. HC Wainwright restated a “buy” rating and issued a $570.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, October 10th. Oppenheimer restated an “outperform” rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Needham & Company LLC boosted their price objective on shares of Alnylam Pharmaceuticals from $377.00 to $478.00 and gave the company a “buy” rating in a report on Thursday, July 31st. Finally, Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the company a “buy” rating in a report on Friday, August 1st. Twenty-three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $478.67.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.